CN103585151A - Famotidine and dexibuprofen compound tablets and preparation method thereof - Google Patents
Famotidine and dexibuprofen compound tablets and preparation method thereof Download PDFInfo
- Publication number
- CN103585151A CN103585151A CN201310603105.1A CN201310603105A CN103585151A CN 103585151 A CN103585151 A CN 103585151A CN 201310603105 A CN201310603105 A CN 201310603105A CN 103585151 A CN103585151 A CN 103585151A
- Authority
- CN
- China
- Prior art keywords
- famotidine
- ibuprofen
- complex tablet
- weight
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides famotidine and dexibuprofen compound tablets and a preparation method thereof. The compound tablets consist of dexibuprofen, famotidine, a disintegrating agent, a diluent, a lubricant and a glidant, wherein the weight ratio of the famotidine to the dexibuprofen is 1: (29-31). The preparation method comprises the following steps: the famotidine is mixed with the diluent and the disintegrating agent, and is added with adhesive for palletizing by the wet method, then is dried to prepare famotidine particles; the dexibuprofen is mixed with the diluent and the disintegrating agent to prepare dexibuprofen particles; the famotidine particles are mixed with the dexibuprofen particles evenly to obtain mixed particles I; the lubricant and the glidant are added in the mixed particles I for evenly mixing to obtain mixed particles II; and the mixed particles II are compressed to form the tablets. The famotidine and dexibuprofen compound tablets have the advantages of better curative effect, quicker effect achievement and small dosage, and can be directly taken orally to treat adult rheumatic arthritis and osteoarthritis.
Description
Technical field
The present invention relates to a kind of complex tablet and preparation method thereof, be specifically related to complex tablet of a kind of famotidine and (S)-ibuprofen and preparation method thereof.
Background technology
Ibuprofen is the derivant of benzenpropanoic acid, being medicine safely and effectively in traditional NSAIDs, is the first ladder medicine that the medication of pain ladder is recommended, in structure containing an asymmetric carbon atom, in molecule, have two enantiomer, its active component is (S)-ibuprofen.Ibuprofen can cause gastritis, dyspepsia and gastric duodenal ulcer after taking.And famotidine is the medicine due to treatment heartburn, ulcer and esophagitis, ibuprofen is made after complex tablet and can be reduced and even eliminate this side effect together with famotidine.
The complex tablet Duexis being comprised of ibuprofen and famotidine of in April, 2011 U.S. FDA approval Liao You Horizon pharmaceutical Co. Ltd exploitation, for being reduced to the disease S&S of human rheumatoid arthritis and Human Osteoarthritis and reducing upper gastrointestinal ulcer developing risk.
Summary of the invention
The object of the present invention is to provide a kind of the have famotidine of better curative effect and complex tablet of (S)-ibuprofen and preparation method thereof.
Object of the present invention is achieved through the following technical solutions:
First aspect, the invention provides the complex tablet of a kind of famotidine and (S)-ibuprofen, (S)-ibuprofen, famotidine, disintegrating agent, diluent, binding agent, lubricant and fluidizer, consist of, the weight ratio of described famotidine and described (S)-ibuprofen is 1:(29 ~ 31).
Preferably, described disintegrating agent is selected from one or more in starch, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, and the percentage ratio that the weight of described disintegrating agent accounts for described complex tablet gross weight is 2 ~ 20%.
Preferably, described diluent is selected from one or more in pregelatinized Starch, starch, microcrystalline Cellulose, lactose, sucrose, and the percentage ratio that the weight of described diluent accounts for described complex tablet gross weight is 10 ~ 90%.
Preferably, described binding agent is selected from one or more in starch, polyvidone, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, and the percentage ratio that the weight of described binding agent accounts for described complex tablet gross weight is 0.2 ~ 10%.
Preferably, described lubricant is selected from one or more in magnesium stearate, calcium stearate, sodium benzoate, palmitic acid stearic acid ester of glycerol, Polyethylene Glycol, hydrogenated cottonseed oil, Oleum Ricini, and the percentage ratio that the weight of described lubricant accounts for described complex tablet gross weight is 0.2 ~ 2%.
Preferably, described fluidizer is selected from one or more in colloidal silica, Pulvis Talci, corn starch, and the percentage ratio that the weight of described fluidizer accounts for described complex tablet gross weight is 0.5 ~ 10%.
First aspect, the invention provides the preparation method of the complex tablet of a kind of above-mentioned famotidine and (S)-ibuprofen, comprises the following steps:
Step (1), adds binding agent after mixing by famotidine with diluent, disintegrating agent, and wet granulation is dried, and prepares famotidine granule;
Step (2), (S)-ibuprofen and diluent, disintegrating agent are mixed with (s)-ibuprofen granules;
Step (3), mixes described famotidine granule and described (s)-ibuprofen granules, obtains hybrid particles I;
Step (4) adds lubricant and fluidizer in described hybrid particles I, mixes, and obtains hybrid particles II;
Step (5), compresses described hybrid particles II, forms tablet, obtains.
Compared with prior art, the present invention has following beneficial effect: (S)-ibuprofen is compared with waiting dosage ibuprofen, there is better curative effect, smaller dose can reach therapeutical effect, the former dosage 300mg and 600mg and the latter's 400mg and the therapeutic equivalence of 800mg, (S)-ibuprofen toleration is better, and before and after treatment, hemogram, hepatic and renal function are without significant change.Therefore, compare with ibuprofen, (S)-ibuprofen better efficacy, onset are faster, and small amount just can reach the curative effect of ibuprofen, meanwhile, aspect safety and medicine kinetics, is all being better than ibuprofen.Famotidine can reduce the gastric acid secretion that can cause gastric duodenal ulcer, can improve the gastrointestinal safety of (S)-ibuprofen, but can not cut down the effect that this medicine reduces pain and inflammation.Diluent is that the unit weight in order to increase for molding adds the excipient of pharmaceutical composition to reach desired wt.Binding agent is the excipient that gives the adhesion properties that the one-tenth of pharmaceutical composition divides.Disintegrating agent be incorporated in pharmaceutical composition, guarantee that said composition has the excipient of acceptable disintegration rate in environment for use.Fluidizer in order to keep composition flow of powder in film-making process, prevent the formation of caking and be included in the excipient in pharmaceutical composition.The complex tablet that (S)-ibuprofen provided by the invention and famotidine are made, can be directly oral adult's rheumatoid arthritis and the osteoarthritis of being used for the treatment of, more can meet the requirement of patient treatment.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is described in detail.Following examples will contribute to those skilled in the art further to understand the present invention, but not limit in any form the present invention.It should be pointed out that to those skilled in the art, without departing from the inventive concept of the premise, can also make certain adjustments and improvements.These all belong to protection scope of the present invention.
embodiment 1
| ? | Composition | Milligram/unit |
| 1 | Famotidine | 10 |
| 2 | Microcrystalline Cellulose PH101 | 73 |
| 3 | Starch | 5 |
| 4 | Hydroxypropyl cellulose | 2 |
| 5 | Purified water | In addition |
| ? | Sub-total amount | 90 |
| 6 | (S)-ibuprofen | 300 |
| 7 | Microcrystalline Cellulose PH102 | 70 |
| 8 | Low-substituted hydroxypropyl cellulose | 15 |
| 9 | Cross-linking sodium carboxymethyl cellulose | 15 |
| ? | Sub-total amount | 400 |
| 10 | Colloidal silica | 5 |
| 11 | Magnesium stearate | 5 |
| ? | Total amount | 500 |
(1) by item 1-3(famotidine, microcrystalline Cellulose PH101, starch) cross respectively 80 mesh sieves, add in V-Mixer and mix 15 minutes;
(2) item 4 use purified water are dissolved and obtained binding agent;
(3) mixture in step (1) is transferred to low shear granulation machine;
(4) under the low speed, start granulator, add binding agent, frequently check wet grain, until wet granulation reaches terminal, the amount of binder of interpolation is 200ml;
(5) adopt drying baker dry, baking temperature is set to 50 ℃;
(6) basin is covered by aluminium foil, and wet grain is evenly deployed on aluminium foil, and is dried at 50 ℃, until water content is lower than 3% dry stopping;
(7) dry granule is crossed 30 mesh sieves and is carried out granulate, obtains famotidine granule;
(8) 6-9 crosses respectively 80 mesh sieves and enters V-Mixer mixing 15 minutes, obtains (s)-ibuprofen granules;
(9) item 7 joins in the (s)-ibuprofen granules mixing after weighing according to formula proportion, continues to mix 15 minutes;
(10) in item 9, add again micropowder silica gel and the magnesium stearate of formula ratio, mix 10 minutes;
(11) granule of preparing carries out tabletting, obtains famotidine (S)-ibuprofen sheet.
embodiment 2
| ? | Composition | Milligram/unit |
| 1 | Famotidine | 9 |
| 2 | Microcrystalline Cellulose PH101 | 72 |
| 3 | Starch | 5 |
| 4 | Hydroxypropyl cellulose | 2 |
| 5 | Purified water | In addition |
| ? | Sub-total amount | 90 |
| 6 | (S)-ibuprofen | 310 |
| 7 | Microcrystalline Cellulose PH102 | 60 |
| 8 | Low-substituted hydroxypropyl cellulose | 15 |
| 9 | Cross-linking sodium carboxymethyl cellulose | 15 |
| ? | Sub-total amount | 400 |
| 10 | Colloidal silica | 5 |
| 11 | Magnesium stearate | 5 |
| ? | Total amount | 500 |
(1) by item 1-3(famotidine, microcrystalline Cellulose PH101, starch) cross respectively mesh sieve, add in V-Mixer and mix 15 minutes;
(2) item 4 use purified water are dissolved and obtained binding agent;
(3) mixture in step (1) is transferred to low shear granulation machine;
(4) under the low speed, start granulator, add binding agent, frequently check wet grain, until wet granulation reaches terminal, the amount of binder of interpolation is 200ml;
(5) adopt drying baker dry, baking temperature is set to 50 ℃;
(6) basin is covered by aluminium foil, and wet grain is evenly deployed on aluminium foil, and is dried at 50 ℃, until water content is lower than 3% dry stopping;
(7) dry granule is crossed 30 mesh sieves and is carried out granulate, obtains famotidine granule;
(8) 6-9 crosses respectively 80 mesh sieves and enters V-Mixer mixing 15 minutes, obtains (s)-ibuprofen granules;
(9) item 7 joins in the (s)-ibuprofen granules mixing after weighing according to formula proportion, continues to mix 15 minutes;
(10) in item 9, add again micropowder silica gel and the magnesium stearate of formula ratio, mix 10 minutes;
(11) granule of preparing carries out tabletting, obtains famotidine (S)-ibuprofen sheet.
embodiment 3
| ? | Composition | Milligram/unit |
| 1 | Famotidine | 11 |
| 2 | Microcrystalline Cellulose PH101 | 71 |
| 3 | Starch | 5 |
| 4 | Hydroxypropyl cellulose | 2 |
| 5 | Purified water | In addition |
| ? | Sub-total amount | 90 |
| 6 | (S)-ibuprofen | 320 |
| 7 | Microcrystalline Cellulose PH102 | 60 |
| 8 | Low-substituted hydroxypropyl cellulose | 10 |
| 9 | Cross-linking sodium carboxymethyl cellulose | 10 |
| ? | Sub-total amount | 400 |
| 10 | Colloidal silica | 5 |
| 11 | Magnesium stearate | 5 |
| ? | Total amount | 500 |
(1) by item 1-3(famotidine, microcrystalline Cellulose PH101, starch) cross respectively 80 mesh sieves, add in V-Mixer and mix 15 minutes;
(2) item 4 use purified water are dissolved and obtained binding agent;
(3) mixture in step (1) is transferred to low shear granulation machine;
(4) under the low speed, start granulator, add binding agent, frequently check wet grain, until wet granulation reaches terminal, the amount of binder of interpolation is 200ml;
(5) adopt drying baker dry, baking temperature is set to 50 ℃;
(6) basin is covered by aluminium foil, and wet grain is evenly deployed on aluminium foil, and is dried at 50 ℃, until water content is lower than 3% dry stopping;
(7) dry granule is crossed 30 mesh sieves and is carried out granulate, obtains famotidine granule;
(8) 6-9 crosses respectively 80 mesh sieves and enters V-Mixer mixing 15 minutes, obtains (s)-ibuprofen granules;
(9) item 7 joins in the (s)-ibuprofen granules mixing after weighing according to formula proportion, continues to mix 15 minutes;
(10) in item 9, add again micropowder silica gel and the magnesium stearate of formula ratio, mix 10 minutes;
(11) granule of preparing carries out tabletting, obtains famotidine (S)-ibuprofen sheet.
embodiment 4
| ? | Composition | Milligram/unit |
| 1 | Famotidine | 11 |
| 2 | Microcrystalline Cellulose PH101 | 72 |
| 3 | Starch | 4 |
| 4 | Hydroxypropyl cellulose | 2 |
| 5 | Purified water | In addition |
| ? | Sub-total amount | 90 |
| 6 | (S)-ibuprofen | 330 |
| 7 | Microcrystalline Cellulose PH102 | 50 |
| 8 | Low-substituted hydroxypropyl cellulose | 15 |
| 9 | Cross-linking sodium carboxymethyl cellulose | 15 |
| ? | Sub-total amount | 400 |
| 10 | Colloidal silica | 5 |
| 11 | Magnesium stearate | 5 |
| ? | Total amount | 500 |
(1) by item 1-3(famotidine, microcrystalline Cellulose PH101, starch) cross respectively 80 mesh sieves, add in V-Mixer and mix 15 minutes;
(2) item 4 use purified water are dissolved and obtained binding agent;
(3) mixture in step (1) is transferred to low shear granulation machine;
(4) under the low speed, start granulator, add binding agent, frequently check wet grain, until wet granulation reaches terminal, the amount of binder of interpolation is 200ml;
(5) adopt drying baker dry, baking temperature is set to 50 ℃;
(6) basin is covered by aluminium foil, and wet grain is evenly deployed on aluminium foil, and is dried at 50 ℃, until water content is lower than 3% dry stopping;
(7) dry granule is crossed 30 mesh sieves and is carried out granulate, obtains famotidine granule;
(8) 6-9 crosses respectively 80 mesh sieves and enters V-Mixer mixing 15 minutes, obtains (s)-ibuprofen granules;
(9) item 7 joins in the (s)-ibuprofen granules mixing after weighing according to formula proportion, continues to mix 15 minutes;
(10) in item 9, add again micropowder silica gel and the magnesium stearate of formula ratio, mix 10 minutes;
(11) granule of preparing carries out tabletting, obtains famotidine (S)-ibuprofen sheet.
?
embodiment 5
| ? | Composition | Milligram/unit |
| 1 | Famotidine | 11 |
| 2 | Microcrystalline Cellulose PH101 | 72 |
| 3 | Starch | 4 |
| 4 | Hydroxypropyl cellulose | 2 |
| 5 | Purified water | In addition |
| ? | Sub-total amount | 90 |
| 6 | (S)-ibuprofen | 330 |
| 7 | Microcrystalline Cellulose PH102 | 50 |
| 8 | Low-substituted hydroxypropyl cellulose | 20 |
| 9 | Cross-linking sodium carboxymethyl cellulose | 10 |
| ? | Sub-total amount | 400 |
| 10 | Colloidal silica | 5 |
| 11 | Magnesium stearate | 5 |
| ? | Total amount | 500 |
(1) by item 1-3(famotidine, microcrystalline Cellulose PH101, starch) cross respectively 80 mesh sieves, add in V-Mixer and mix 15 minutes;
(2) item 4 use purified water are dissolved and obtained binding agent;
(3) mixture in step (1) is transferred to low shear granulation machine;
(4) under the low speed, start granulator, add binding agent, frequently check wet grain, until wet granulation reaches terminal, the amount of binder of interpolation is 200ml;
(5) adopt drying baker dry, baking temperature is set to 50 ℃;
(6) basin is covered by aluminium foil, and wet grain is evenly deployed on aluminium foil, and is dried at 50 ℃, until water content is lower than 3% dry stopping;
(7) dry granule is crossed 30 mesh sieves and is carried out granulate, obtains famotidine granule;
(8) 6-9 crosses respectively 80 mesh sieves and enters V-Mixer mixing 15 minutes, obtains (s)-ibuprofen granules;
(9) item 7 joins in the (s)-ibuprofen granules mixing after weighing according to formula proportion, continues to mix 15 minutes;
(10) in item 9, add again micropowder silica gel and the magnesium stearate of formula ratio, mix 10 minutes;
(11) granule of preparing carries out tabletting, obtains famotidine (S)-ibuprofen sheet.
implementation result
The pharmacologically active of finding ibuprofen through research comes from d-isomer, compare with ibuprofen such as dosage such as grade, it has better curative effect, smaller dose can reach therapeutical effect, the former dosage 300mg and 600mg and the latter's 400mg and the therapeutic equivalence of 800mg, be all better than ibuprofen aspect safety and medicine kinetics.Therefore, compare with ibuprofen, (S)-ibuprofen better efficacy, onset are faster.Meanwhile, the improvement of the indexs such as rest pain, articular pain, arthroncus and joint-improving, also higher than ibuprofen, is illustrated to (S)-ibuprofen has stronger pain relieving, antiinflammatory, detumescence effect, relief of symptoms more effectively, curative effect is better than ibuprofen, and toleration is better; Before and after treatment, hemogram, hepatic and renal function, without significant change, illustrate that its safety is better.Therefore, (S)-ibuprofen has antiinflammatory and pain relieving effect and small amount and just can reach the curative effect of ibuprofen.Famotidine can reduce the gastric acid secretion that can cause gastric duodenal ulcer, can improve the gastrointestinal safety of (S)-ibuprofen, but can not cut down the effect that this medicine reduces pain and inflammation.Diluent is that the unit weight in order to increase for molding adds the excipient of pharmaceutical composition to reach desired wt.Binding agent is the excipient that gives the adhesion properties that the one-tenth of pharmaceutical composition divides.Disintegrating agent be incorporated in pharmaceutical composition, guarantee that said composition has the excipient of acceptable disintegration rate in environment for use.Fluidizer is in order to keep composition flow of powder in film-making process, prevents the formation of caking and be included in the excipient in pharmaceutical composition.The invention provides (S)-ibuprofen and famotidine is made complex tablet, can be directly oral adult's rheumatoid arthritis and the osteoarthritis of being used for the treatment of, more can meet the requirement of patient treatment.
Above specific embodiments of the invention are described.It will be appreciated that, the present invention is not limited to above-mentioned specific implementations, and those skilled in the art can make various distortion or modification within the scope of the claims, and this does not affect flesh and blood of the present invention.
Claims (7)
1. the complex tablet with famotidine and (S)-ibuprofen, it is characterized in that, (S)-ibuprofen, famotidine, disintegrating agent, diluent, binding agent, lubricant and fluidizer, consist of, the weight ratio of described famotidine and described (S)-ibuprofen is 1:(29 ~ 31).
2. the complex tablet with famotidine and (S)-ibuprofen according to claim 1, it is characterized in that, described disintegrating agent is selected from one or more in starch, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, and the percentage ratio that the weight of described disintegrating agent accounts for described complex tablet gross weight is 2 ~ 20%.
3. the complex tablet with famotidine and (S)-ibuprofen according to claim 1, it is characterized in that, described diluent is selected from one or more in pregelatinized Starch, starch, microcrystalline Cellulose, lactose, sucrose, and the percentage ratio that the weight of described diluent accounts for described complex tablet gross weight is 10 ~ 90%.
4. the complex tablet with famotidine and (S)-ibuprofen according to claim 1, it is characterized in that, described binding agent is selected from one or more in starch, polyvidone, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, and the percentage ratio that the weight of described binding agent accounts for described complex tablet gross weight is 0.2 ~ 10%.
5. the complex tablet with famotidine and (S)-ibuprofen according to claim 1, it is characterized in that, described lubricant is selected from one or more in magnesium stearate, calcium stearate, sodium benzoate, palmitic acid stearic acid ester of glycerol, Polyethylene Glycol, hydrogenated cottonseed oil, Oleum Ricini, and the percentage ratio that the weight of described lubricant accounts for described complex tablet gross weight is 0.2 ~ 2%.
6. the complex tablet with famotidine and (S)-ibuprofen according to claim 1, it is characterized in that, described fluidizer is selected from one or more in colloidal silica, Pulvis Talci, corn starch, and the percentage ratio that the weight of described fluidizer accounts for described complex tablet gross weight is 0.5 ~ 10%.
7. the preparation method of the complex tablet of famotidine and (S)-ibuprofen described in claim 1 to 6, is characterized in that, comprises the following steps:
Step (1), adds binding agent after mixing by famotidine with diluent, disintegrating agent, and wet granulation is dried, and prepares famotidine granule;
Step (2), (S)-ibuprofen and diluent, disintegrating agent are mixed with (s)-ibuprofen granules;
Step (3), mixes described famotidine granule and described (s)-ibuprofen granules, obtains hybrid particles I;
Step (4) adds lubricant and fluidizer in described hybrid particles I, mixes, and obtains hybrid particles II;
Step (5), compresses described hybrid particles II, forms tablet, obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310603105.1A CN103585151B (en) | 2013-11-26 | 2013-11-26 | Famotidine and dexibuprofen compound tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310603105.1A CN103585151B (en) | 2013-11-26 | 2013-11-26 | Famotidine and dexibuprofen compound tablets and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103585151A true CN103585151A (en) | 2014-02-19 |
| CN103585151B CN103585151B (en) | 2015-03-04 |
Family
ID=50075605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310603105.1A Active CN103585151B (en) | 2013-11-26 | 2013-11-26 | Famotidine and dexibuprofen compound tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585151B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516368A (en) * | 2006-07-18 | 2009-08-26 | 好利用医疗公司 | Methods and medicaments for administration of ibuprofen |
| US20130236538A1 (en) * | 2007-11-30 | 2013-09-12 | Horizonpharma Usa, Inc. | Pharmaceutical compositions of ibuprofen and famotidine |
-
2013
- 2013-11-26 CN CN201310603105.1A patent/CN103585151B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101516368A (en) * | 2006-07-18 | 2009-08-26 | 好利用医疗公司 | Methods and medicaments for administration of ibuprofen |
| US20130236538A1 (en) * | 2007-11-30 | 2013-09-12 | Horizonpharma Usa, Inc. | Pharmaceutical compositions of ibuprofen and famotidine |
Non-Patent Citations (1)
| Title |
|---|
| 罗国庆等: "右旋布洛芬的研究进展", 《医药导报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103585151B (en) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014104671A1 (en) | Pharmaceutical composition with improved stability, containing temozolomide, and preparation method therefor | |
| CN106074406A (en) | A kind of Vonoprazan fumarate dispersible tablet and preparation method thereof | |
| KR101050076B1 (en) | Compositions of Oral Formulations Containing Controlled Release Aceclofenac and Methods for Making the Same | |
| CA2530788A1 (en) | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives | |
| CN101564402A (en) | Rehabilitation new dispersing tablet and preparation method thereof | |
| WO2023070985A1 (en) | Abidor hydrochloride tablet and preparation method therefor | |
| CN103263395A (en) | Telmisartan tablet preparation and preparation method thereof | |
| CN103610658A (en) | Immunomodulator slow-release preparation and preparation method thereof | |
| CN104958290A (en) | Tofogliflozin and metformin compound preparation and preparation method thereof | |
| CN103585151B (en) | Famotidine and dexibuprofen compound tablets and preparation method thereof | |
| CN102294031B (en) | Pharmaceutical formulation comprising proton pump inhibitor, NSAID and antacids | |
| CN103961351A (en) | Preparation method of amoxicillin and clavulanate potassium tablets | |
| CN102784154B (en) | Mesalazine enteric coated tablet and preparation method thereof | |
| CN102525878A (en) | Tranexamic acid sustained-release solid composition and preparation method thereof | |
| CN102451171B (en) | Tindazole vaginal effervescent tablet and preparation method thereof | |
| KR101076648B1 (en) | Controlled-release Aceclofenac Containing Oral Drug Preparations and it's Manufacturing Process | |
| CN103110601B (en) | Gliclazide gastric floating tablet and preparation method thereof | |
| CN101653423A (en) | Lacidipine tablets and preparation method thereof | |
| CN102357084A (en) | Enalapril maleate tablet composition and its preparation and use | |
| CN101642442A (en) | Tablets for preventing and curing osteoarthritis and preparation method thereof | |
| CN102813661B (en) | Application for glycyrrhetinic acid derivatives | |
| CN101040850A (en) | Colchicine sustained-release pellets and the preparing method | |
| CN105012247A (en) | Diacerein composition and preparation method thereof | |
| CN105030707A (en) | Method for preparing clotrimazole buccal tablets on basis of all-powder direct pressing of modified glucose | |
| CN110787155A (en) | Itopride hydrochloride pharmaceutical composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 230088, Anhui, Hefei Province opened the District busy road, industrial investment, standing industrial Plaza B-9 Applicant after: ANHUI LIANCHUANG BIOLOGICAL MEDICINE CO., LTD. Address before: 230088, Anhui, Hefei Province opened the District busy road, industrial investment, standing industrial Plaza B-9 Applicant before: Anhui Lianchuang Pharmaceutical Chemistry Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ANHUI LIANCHUANG PHARMACEUTICAL CHEMISTRY CO., LTD. TO: ANHUI LIANCHUANG BIOLOGICAL MEDICINE CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |